A review on the role of cyclin dependent kinases in cancers

Ghafouri-Fard, Soudeh; Khoshbakht, Tayyebeh; Hussen, Bashdar Mahmud; Dong, Peixin; Gassler, Nikolaus; Taheri, Mohammad; Baniahmad, Aria; Dilmaghani, Nader Akbari

doi:10.1186/s12935-022-02747-z

Cancer Cell International

Table 5 Function of CDK2 in animal models of cancer

From: A review on the role of cyclin dependent kinases in cancers

Tumor Type	Animal models	Results	References
Acute myeloid leukemia	NOD/SCID mice	∆ CDK1: ↓ tumor growth and ↑ survival of AML-bearing mice	[92]
	6–8-week-old NOD/SCID immunodeficient mice	Chidamide combined with doxorubicin could inhibit HDAC3-AKT-P21-CDK2 signaling pathway and reduce tumor growth	[101]
	4–5-week-old female NOD/SCID mice	∆ CDK2 and ATRA combination therapy: ↓ engraftment of leukemia cells and ↑ primary AML blasts differentiation	[102]
	BALB/c or C57BL/6 mice	∆ CDK2: ↓ proliferation and ↑ senescence, thus delayed MYC/BCL-XL-driven AML	[175]
Bladder cancer	Pathogen-free male BALB/C nude mice	Palbociclib was found to play its anticancer role via Cdk2 activation	[97]
Bladder cancer	4-week-old male BALB/c-nude mice	↑↑ NPTX1: ↓ tumor volume and weight	[105]
Breast cancer	4-week-old BALB/c nude mice	∆ CDK2 and CDK4/6: ↓ proliferation, growth, and ↓ Palbociclib resistance	[98]
	Female BALB/c mice	combination of either CDK2 or EZH2 inhibitor with tamoxifen: ↓ tumor growth and ↑ survival	[99]
	6-week-old female BALB/c nude mice	∆ TROJAN: ↓ tumor growth and tumor volume	[108]
	female NOD-SCID-IL2γR − / − (NSG) mice	Combination PARP and CDK2 inhibition: ↑ tumor regression and survival	[109]
	5–6-week-old female BALB/c-nu mice	↑↑ ACTL6A: ↑ tumor growth K03861 (CDK2 inhibitor) and paclitaxel: ↓ growth	[110]
	NOD/SCID mice	4-AAQB treatment: ↓ tumor growth via suppressing CDK2 and CDK4	[111]
	female BALB/c mice	∆ Lnc712: ↓ tumor growth Via suppressing CDK2	[116]
	female NOD/SCID mice	ALT + PD combination: ↓ tumor growth via inhibiting both cdk4 and cdk2	[117]
	female BALB/c nude mice	Higenamine and cucurbitacin B: ↓ tumor growth via suppressing the interaction of AKT and CDK2	[120]
	5–6-week old female athymic nu/nu mice	CDK2/9 inhibitors, CYC065 and eribulin combination: ↓ tumor volume	[124]
Cervical cancer	4-week-old BALB/C nude mice	∆ hsa_circ_0000520: ↓ tumor volume and weight	[128]
Cervical cancer	4–6-week-old female BALB/c nude mice	∆ circZFR: ↓ tumor growth	[130]
Cholangiocarcinoma	6-week old NSG mice	Dinaciclib and gemcitabine combination: ↓ tumor growth	[132]
Colorectal cancer	nude mice	↑↑ NPTX1: ↓ tumor growth via downregulating CDK2	[133]
	8–10-week-old SCID mice	Dual CDK2/9 inhibition: ↓ tumor growth	[136]
	5-week-old athymic nude BALB/c mice	∆ SLCO4A1-AS1: ↓ tumor growth	[137]
Gastric cancer	4–6-week-old nude BALB/c mice	∆ LINC01021: ↓ tumor volume and weight	[139]
Glioma	6-week-old male BALB/c mice	∆ LINC00958: ↓ tumor growth	[142]
Glioma	male BALB/c nude mice	∆ HSP90AA1-IT1: ↓ tumor growth	[143]
Hepatocellular carcinoma	4-week-old female BALB/c-nu, nude mice	∆ HNRNPU: ↓ tumor volume and weight	[145]
	6–8-week-old male BALB/C nude mice	∆ OLA1: ↓ tumor growth and weight	[148]
	Nude mice	↑↑ TPT1-AS1: ↓ tumor growth	[149]
	4-week-old athymic BALB/c mice	↑↑ miR-155: ↑ tumor weight	[153]
Lung cancer	6–8-week-old male immunocompetent 129S2/SVPasCrl mice	CDK2/9 inhibitor, CCT68127: ↓ tumor growth	[157]
Lung cancer	BALB/c athymic nude mice	PROS reduced tumor volumes and weights via inhibiting STAT3/ VEGF/ CDK2 axis	[158]
Medulloblastoma	6–8-week-old female Athymic Nude-Foxn1nu mice	BET bromodomain inhibition and CDK2 inhibition: ↓ tumor growth	[160]
Ovarian cancer	6-week old BALB/nude mice	↑↑ PLAC2: ↑ tumor growth via regulating CDK2	[165]
Renal cell carcinoma	4–6-week-old BALB/c athymic nude mice	nobiletin and palbociclib combination: ↓ tumor growth	[168]
Renal cell carcinoma	5-week-old female BALB/c nude mice	∆ WTAP: ↓ tumor growth	[68]
Soft tissue leiomyosarcoma	5-week-old female BALB/c nude mic	∆ PLA2G10: ↓ tumor growth and weight	[170]
T-cell acute lymphoblastic leukemia	8-week-old female C57BL/6J mice	∆ SIRT1: ↑ lifespan of T-ALL model mice	[171]

∆ knock-down, deletion or inhibition, NOD/SCID nonobese diabetic/severe combined immunodeficiency, AML Acute myeloid leukemia, NSG NOD scid gamma, T-ALL T-cell acute lymphoblastic leukemia, SCID severe combined immunodeficient, NSG NOD scid gamma, T-ALL T-cell acute lymphoblastic leukemia, SCID severe combined immunodeficient)

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com